News Genmab ends lung cancer drug development Genmab has decided to stop development of a drug for cancer, acasunlimab for non-small cell lung cancer, following a review of its pipeline.
News Biosimilars unlock use of bevacizumab in bowel cancer by NHS More than 20 years after its approval, NICE has backed the use of bevacizumab as a treatment for colorectal cancer for the first time.
News Ipsen licenses Simcere ADC in $1bn-plus deal Deal-hungry Ipsen is at it again, pledging around $1bn for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere.
News AZ's ATR inhibitor ceralasertib flunks lung cancer test AstraZeneca has had a setback in its oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 lung cancer trial.
News Ambros' $125m for pain disorder drug, and other financings Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.
News J&J's subcutaneous Rybrevant cleared by FDA J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.
News ESC26: Isomab safety evidence on blood vessel growth for CAD Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
